• 0.63G OEM New, Compound α -Ketoacid Tablets
  • 0.63G OEM New, Compound α -Ketoacid Tablets
  • 0.63G OEM New, Compound α -Ketoacid Tablets
  • 0.63G OEM New, Compound α -Ketoacid Tablets
  • 0.63G OEM New, Compound α -Ketoacid Tablets
  • 0.63G OEM New, Compound α -Ketoacid Tablets

0.63G OEM New, Compound α -Ketoacid Tablets

Application: Internal Medicine
Usage Mode: For oral administration
Suitable for: Elderly, Children, Adult
State: Solid
Shape: Tablet
Type: Biological Products
Samples:
US$ 0/Piece 1 Piece(Min.Order)
| Request Sample
Customization:

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company

Basic Info.

Model NO.
AMC12064
Pharmaceutical Technology
Chemical Synthesis
OEM
Accept
Registration Dossiers
Available
Transport Package
10′s/Box
Specification
Compound
Trademark
MEDIPHARM/OEM
Origin
China
HS Code
3004909099
Production Capacity
1000000 Boxes/Month

Product Description

Product Description

 

Product Description

0.63G OEM New, Compound α -Ketoacid Tablets

DESCRIPTION

This compound tablets contain 4 kinds of Calcium Amino Acid, 1 kind of Calcium Hydroxyl-amino Acid and 5 kinds of Amino Acids.

CHARACTERS
Compound α-Ketoacid Tablets are yellow film coated. The tablet color is white after film removed. For each tablet, the total nitrogen content is 36mg and the total calcium content reaches 1.25mmol which equals approximately to 50mg.

PHARMACOLOGY AND TOXICOLOGY

Compound α-Ketoacid Tablets can supply the essential amino acids and reduce the intake of ammonia nitrogen. Ketone or hydroxyamino acid does not contain amidogen, which can help them utilize the nitrogen from non-essential amino acids to transfer  into amino acids. This can reduce the synthesis of urea as well as the accumulation  of the uremic toxic products. Ketone or hydroxyamino does not cause the ultrafiltration of remnant nephron, alleviate the renal hyperphosphatemia and secondary hyperparathyroidism and improve the status of renal osteodystrophy. With the low-protein diet together, Compound α-Ketoacid Tablets can reduce the intake of nitrogen and at the same time avoid the adverse consequences caused by insufficient protein intake and malnutrition.The results of toxicology researches indicate that Compound α-Ketoacid Tablets has low toxicity. Chronic toxicology researches show that minimum toxicity dose of dog is 1200 mg/day and rat 2700 mg/day. After conversion, the dosage for the human  body (70 kg) is 84 g/day according to dog dosage and 189 g/day according to rat dosage.
This product has no embryo toxicity.
 

0.63G OEM New, Compound α -Ketoacid Tablets0.63G OEM New, Compound α -Ketoacid Tablets

0.63G OEM New, Compound α -Ketoacid Tablets0.63G OEM New, Compound α -Ketoacid Tablets0.63G OEM New, Compound α -Ketoacid Tablets0.63G OEM New, Compound α -Ketoacid Tablets

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company
Management System Certification
ISO 9001, GMP, ISO 13485, FSC
Import & Export Mode
Have Own Export License